Melanoma Glycome Regulates the Pro-Oncogenic Properties of Extracellular Galectin-3
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26104882 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Norhan B B Mohammed und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY 10016, USA. Hauptthemen laut MEDLINE: Galectin 3, Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIU Dissertation Year Fellowship, Sigma Xi GIAR, NCI NIH HHS.
Abstract (Originalsprache)
Metastatic melanoma is an aggressive skin cancer with a five-year survival rate of only 35%. Despite recent advances in immunotherapy, there is still an urgent need for the development of innovative therapeutic approaches to improve clinical outcomes of patients with metastatic melanoma. Prior research from our laboratory revealed that loss of the I-branching enzyme β1,6 N-acetylglucosaminyltransferase 2 (GCNT2), with consequent substitution of melanoma surface I-branched poly-N-acetyllactosamines (poly-LacNAcs) with i-linear poly-LacNAcs, is implicated in driving melanoma metastasis. In the current study, we explored the role of galectin-3 (Gal-3), a lectin that avidly binds surface poly-LacNAcs, in dictating melanoma aggressive behavior. Our results show that Gal-3 favors binding to i-linear poly-LacNAcs, while enforced GCNT2/I-branching disrupts this interaction, thereby suppressing Gal-3-dependent malignant characteristics, including extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway activation, BCL2 expression, cell proliferation, and migration. This report establishes the crucial role of extracellular Gal-3 interactions with i-linear glycans in promoting melanoma cell aggressiveness, placing GCNT2 as a tumor suppressor protein and suggesting both extracellular Gal-3 and i-linear glycans as potential therapeutic targets for metastatic melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY 10016, USA.
- Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.
ORCID-Profile: Charles J Dimitroff
Förderung
- FIU Dissertation Year Fellowship
- Sigma Xi GIAR
- NCI NIH HHS
- FIU Presidential Fellowship
- NIH HHS
- NIH/NCI
Zitieren
APA
Mohammed, N. B. B., Shil, R. K., & Dimitroff, C. J. (2025). Melanoma Glycome Regulates the Pro-Oncogenic Properties of Extracellular Galectin-3. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26104882
Vancouver
Mohammed NBB, Shil RK, Dimitroff CJ. Melanoma Glycome Regulates the Pro-Oncogenic Properties of Extracellular Galectin-3. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26104882
BibTeX
@article{Mohammed2025,
author = {Mohammed, Norhan B B and Shil, Rajib K and Dimitroff, Charles J},
title = {Melanoma Glycome Regulates the Pro-Oncogenic Properties of Extracellular Galectin-3},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26104882}
}
EUVIMED